2-Triazenoazaindoles: A novel class of triazenes inducing transcriptional down-regulation of EGFR and HER-2 in human pancreatic cancer cells

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 914-922

  Kreutzer, Jan N ^a   Salvador, Alessia ^b   Diana, Patrizia ^c   Cirrincione, Girolamo ^c   Vedaldi, Daniela ^b   Litchfield, David W ^d   Issinger, Olaf Georg ^a   Guerra, Barbara ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d WESTERN UNIVERSITY   (Canada)

Author keywords

2 triazenoazaindoles; Cell death; EGFR; HER 2; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; AS 104; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE I; CASPASE 3; CASPASE 7; CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETHYL 2 (3,3 DIBENZYL 1 TRIAZENYL) 1H PYRIDO(2,3 C)PYRROLO 3 CARBOXYLATE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; LC3B I PROTEIN; LC3B II PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIM3 PROTEIN; PROTEIN KINASE B; SERINE; STRESS ACTIVATED PROTEIN KINASE; THREONINE; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; INDOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; BIOSYNTHESIS; CELL GROWTH; DRUG EFFECT; ENZYMOLOGY; GENETICS; MOLECULARLY TARGETED THERAPY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; AUTOPHAGY; CARCINOMA, PANCREATIC DUCTAL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRIAZENES;

EID: 84858625349     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1272     Document Type: Article

References (37)

1. Wong HH and Lemoine NR: Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nature 6: 412?-422, 2009.
2. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. Cancer J Clin 60: 277-300, 2010.
3. Ahrendt SA and Pitt HA: Surgical management of pancreatic cancer. Oncology 16: 725-734, 2002.
4. Burris HA III: Recent updates on the role of chemotherapy in pancreatic cancer. Semin Oncol 32: S1-S3, 2005.
5. Mackenzie RP and McCollum AD: Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev. Anticancer Ther 9: 1473-1485, 2009.
6. Bardeesy N and DePinho RA: Pancreatic cancer biology and genetics. Nature 2: 897-909, 2002. (Pubitemid 37328891)
7. Buchholz M and Gress TM: Molecular changes in pancreatic cancer. Expert Rev Anticancer Ther 9: 1487-1497, 2009.
8. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M and Beger HG: Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90: 1352?-1360, 1992.
9. Watanabe M, Nobuta A, Tanaka J and Asaka M: An effect of K-ras gene mutation on epidermal growth factor receptor signal transduction in PANC-1 pancreatic carcinoma cells. Int J Cancer 67: 264-268, 1996. (Pubitemid 26274159)
10. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P and Korc M: Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 202: 1705-1709, 1994. (Pubitemid 24265968)
11. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG and Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13: 565-569, 1993.
12. Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR, Meijer GA and Hidalgo M: Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 68: 2841-2849, 2008. (Pubitemid 351556283)
13. Kim IY, Kang YS, Lee DS, Park HJ, Choi EK, Oh YK, Son HJ and Kim JS: Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release 140: 55-60, 2009.
14. te Velde EA, Franke AC, van Hillegersberg R, Elshof SM, de Weger RW, Borel Rinkes IH and van Diest PJ: HER-familiy gene amplification and expression in resected pancreatic cancer. Eur J Surg Oncol 35: 1098-1104, 2009.
15. Yu D and Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19: 6115-6121, 2000. (Pubitemid 32059461)
16. Diana P, Stagno A, Barraja P, Carbone A, Parrino B, Dall'Acqua F, Vedaldi F, Salvador A, Brun P, Castagliuolo I, Issinger OG and Cirrincione G: Synthesis of trazenoazaindoles: a new class of triazenes with antitumor activity. Chem Med Chem 6: 1291?-1299, 2011.
17. Pham NA, Tsao MS, Cao P and Hedley DW: Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. Pancreas 35: 16?-26, 2007.
18. Kreutzer JN, Ruzzene M and Guerra B: Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells. BMC Cancer 10: 440, 2010.
19. Yde CW, Olsen BB, Meek D, Watanabe N and Guerra B: The regulatory beta subunit of protein kinase CK2 regulates cell-cycle progression at the onset of mitosis. Oncogene 27: 4986?-4997, 2008.
20. Chen G, Kronenberger P, Teugels E and De Grève J: Influence of RT-qPCR primer postion on EGFR interference efficacy in lung cancer cells. Biol Proced Online 11: 13, 2010.
21. Walch A, Specht K, Bink K, Zitzelsberger H, Braselmann H, Bauer M, Aubele M, Stein H, Siewert JR, Höfler H and Werner M: Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adeno- carcinoma sequence of Barrett's esophagus. Lab Invest 81: 791?-801, 2001.
22. Ali S, El-Rayes BF, Sarkar FH and Philip PA: Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase- 2 pathways for pancreatic cancer therapy. Mol Cancer Ther 4: 1943-1951, 2005. (Pubitemid 43056977)
23. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L and Bold RJ: Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 89: 2110-2115, 2003. (Pubitemid 38030911)
24. Sadasivam S, Gupta S, Radha V, Batta K, Kundu TK and Swarup G: Caspase-1 activator Ipaf is a p53-inducible gene involved in apoptosis. Oncogene 24: 627-636, 2005. (Pubitemid 40188567)
25. Orosco A, Fromigué O, Bazille C, Entz-Werle N, Levillain P, Marie PJ and Modrowski D: Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Cancer Res 67: 3708-3715, 2007. (Pubitemid 46762156)
26. Chang L and Karin M: Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001. (Pubitemid 32225829)
27. Rennefhart U, Janakiraman M, Ollinger R and Troppmair J: Stress kinase signaling in cancer: fact or fiction? Cancer Lett 217: 1-9, 2005. (Pubitemid 39642860)
28. Marshall J: Clinical implications of the mechanisms of epidermal growth factor receptor inhibitors. Cancer 107: 1207?-1218, 2006.
29. Bonder VM, Sweeney-Gotsch B, Andreeff M, Mills GB and McConkey DJ: Inhibition of the phosphatidyl inositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1: 989-997, 2002.
30. Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Tanno S, Skele KL, Hoffman JP and Testa JR: Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 87: 470-476, 2002.
31. Dent P, Yacoub A, Fisher PB, Hagan MP and Grant S: MAPK pathways in radiation responses. Oncogene 22: 5885-5896, 2003. (Pubitemid 37176709)
32. Lurje G and Lenz H: EGFR signaling and drug discovery. Oncology 77: 400-410, 2009.
33. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Hayashi A, Souzaki R, Tajiri T, Onimaru M, Manabe T, Ohtsuka T and Tanaka M: High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Int J Oncol 38: 629-641, 2011.
34. Eisenberg-Lerner A, Bialik S, Simon HU and Kimchi A: Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Diff 16: 966-975, 2009.
35. Chadalapaka G, Jutooru I, Burghardt R and Safe F: Drugs that target specificity proteins downregulate epidermal growth factor receptor in bladder cancer cells. Mol Cancer Res 8: 739?-750, 2011.
36. Nishi H, Neta G, Nishi KH, Akers LM, Rikiyama T, Proctor KN, Murphy BA and Johnson AC: Analysis of the epidermal growth factor receptor promoter: the effect of nuclear factor-κB. Int J Mol Med 11: 49-55, 2003.
37. Schmedtje JF, Ji YS, Liu WL, DuBois RN and Runge MS: Hypoxia induces cyclooxigenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272: 601-608, 1997. (Pubitemid 27021200)